Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) will face an 11.5% price cut in August under Japan’s quarterly price review, which basically triggers re-pricing for better-than-expected sales, Jiho learned. This brings down prices for three other I/O agents as well, slapping…
To read the full story
Related Article
- Imfinzi Faces Price Slash of 25%, Polivy 15% in February: Quarterly Re-Pricing
November 16, 2023
- Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
- Keytruda to Get 17.5% Price Cut in February
November 13, 2019
- Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
- Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
August 29, 2019
- Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
August 27, 2019
- Maviret Faces 25% Price Slash in Quarterly Review
November 14, 2018
- Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
REGULATORY
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
- Japan’s 19th Pharmacopoeia Revision Takes Effect
April 13, 2026
- Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
April 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…